Stockwinners Market Radar for October 31, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:02 EDT CNH Industrial to sell its Truckline parts business, terms not stated - CNH Industrial announced that it has agreed the sale of its Truckline parts business in Australia, supporting all European, North American and Japanese makes. Truckline has 22 branches across Australia which are supported by distribution warehouses in Perth, Western Australia and Brisbane, Queensland.

18:24 EDT Columbia Sportswear CEO: China is the largest geographic opportunity for us - In an interview on CNBC's Mad Money, Columbia Sportswear CEO Tim Boyle said: Sorel brand saw 27% y/y growth in Q3... It's going to be a really big brand... We're very excited about Sorel... We're looking forward to great things from Shift... The reception to Shift has been terrific... China is the largest geographic opportunity for the company... We have a great brand recognition in China... We have new management in China...We've been moving products out of China in recent years simply because better opportunities existed elsewhere.

17:48 EDT Mayville Engineering director Christen buys 12.5K shares of common stock - In a regulatory filing, Mayville Engineering disclosed that its director Timothy Christen bought 12.5K shares of common stock on October 30th. The total transaction size was $112K.

17:33 EDT Hudson to acquire controlling stake in OHM Concession Group - Hudson Group announced that it has signed an agreement to acquire a controlling stake in the assets of OHM Concession Group, "an award winning food and beverage concessions operator in North America." The addition of OHM adds notable food and beverage options to Hudson's existing concessions catalog and complements Hudson's existing footprint in the Quick Service Restaurant space. In 2018, OHM generated $62M of revenue. The completion of this agreement is subject to customary closing conditions. The transaction is expected to be completed in Q4 2019 or Q1 2020.

17:26 EDT Stanley Black & Decker officer Robert Raff sells over $554K in company shares - Stanley Black & Decker officer Robert Raff disclosed in a filing that he had sold 3,661 shares of company stock at an average price of $$151.36 per share on October 29. The total transaction value of the sale was $ $554,129.

17:13 EDT Qorvo up 8.5% to $87.74 after Q2 results, Q3 guidance top estimates

17:10 EDT Ra Medical Systems announces completion of audit committee investigation - Ra Medical Systems announced that the audit committee of the board has substantially completed its internal investigation, which was originally announced in August. The committee, assisted by independent legal counsel, Morrison & Foerster LLP, conducted a thorough investigation of allegations raised by an employee, as well as additional matters discovered during the course of the investigation. The audit committee, in reviewing the allegations, identified certain behavior inconsistent with the company's Code of Ethics and Conduct and related policies involving certain current and former executive officers and employees of the company. With respect to current company executives and employees, the committee referred these matters to the board or the company for appropriate action and discipline. The committee made a number of recommendations which the board has adopted, including: separation of certain employees, implementing additional and enhanced policies and training, strengthening the company's quality regulatory systems, and adopting certain enhanced controls related to the matters investigated. In addition, the company has continued to take steps in an effort to improve the performance and reliability of the company's DABRA laser system, including hiring a VP, Quality, Regulatory and Clinical, conducting extensive internal and external audits of its quality systems, clinical trial data and manufacturing process, as well as initiating the previously announced voluntary recall of DABRA catheters. Based on the results of the investigation, the company is in the process of evaluating the impact of the results of the investigation on its previously issued or announced financial statements, and its internal controls over financial reporting and compliance procedures.

17:07 EDT First Business Financial appoints Brad Quade Deputy Chief Credit Officer - First Business Financial Services announced that Brad Quade has been hired as Deputy Chief Credit Officer of First Business Financial Services. Quade has over 30 years of experience in the banking industry, having worked at both publicly traded and privately-owned institutions. Corey Chambas, President & CEO of First Business Financial Services, said. "As part of succession management, Brad will work closely with existing Chief Credit Officer, Michael Losenegger, and the credit team. Our plan is for Brad to assume the role of Chief Credit Officer and Michael to reduce his responsibilities and serve in a senior credit officer role by March 31, 2020."

17:03 EDT Community Healthcare increases quarterly dividend to 41.5c per share - Community Healthcare announced that its board has increased its common stock cash dividend for the quarter ended September 30. This dividend, in the amount of 41.5c per share, is payable on November 29 to shareholders of record on November 15. This dividend rate equates to an annualized dividend of $1.66 per share.

16:35 EDT PennyMac Financial initiates 12c per share quarterly dividend - This dividend will be paid on November 29, 2019, to common stockholders of record as of November 15, 2019. The dividend level will be reviewed each quarter and determined based on a number of factors, including, among other things, PennyMac Financial's earnings, liquidity, growth outlook, the capital required to support ongoing growth opportunities, the forward-looking economic environment, and compliance with other internal and external requirements.

16:34 EDT Amerisafe declares special cash dividend of $3.50 per share - Amerisafe announced that its board had declared a special cash dividend of $3.50 per share. The special cash dividend will be payable on November 20 to shareholders of record as of November 13. The board also declared a regular quarterly dividend of 25c per share, payable on December 27 to shareholders of record as of December 13.

16:33 EDT Magellan Health names Kenneth J. Fasola CEO - Magellan Health announced the company's board of directors has appointed Kenneth J. Fasola as Chief Executive Officer, effective November 14, 2019. Fasola will succeed the current CEO Barry M. Smith, who will remain to assist with the transition as needed.

16:32 EDT Assurant acquires CPR, terms not disclosed - Assurant announced it has acquired MMI-CPR LLC, which operates as Cell Phone Repair, one of the largest global franchisors of mobile device repair stores with more than 700 locations. The CPR franchise provides a wide variety of same-day electronic device repairs and offers consumers the ability to sell and buy devices at their local CPR store. Assurant acquired CPR from a subsidiary of investment firm Merrymeeting Group and a third party. Financial terms of the transaction were not disclosed.

16:30 EDT Builders FirstSource sees normalized gross margin to remain above 26% - "As we enter the end of the peak home buying season, the overall market outlook continues to improve. Homebuilders are increasingly catering to the demands of buyers with a more affordable and right-sized product. Our leadership in ongoing growth initiatives and investments in value-added products enable us to provide productivity solutions to help our customers pivot their offering to the demands of homebuyers. The above market growth in higher margin sales has favorably shifted our sales mix so that we expect normalized gross margin to remain above 26 percent in a stable commodity environment. The implementation of our strategic plan has positioned us to continue to deliver strong results as we execute on our operational excellence programs and build a stronger, more agile organization. I would like to thank our fifteen thousand team members for the milestones achieved this quarter and look forward to building on our strengths in the future," concluded Mr. Crow.

16:29 EDT KeyCorp's Harris sells 173,777 common shares - In a regulatory filing, KeyCorp general counsel Paul N. Harris disclosed the sale of 173,777 common shares of the company at a price of $18.50 per share.

16:26 EDT Pinterest falls over 18% to $20.51 per share after Q3 earnings miss

16:25 EDT Bright Horizons, GP Strategies enter exclusive partnership - Bright Horizons (BFAM) and GP Strategies (GPX) announced a unique partnership that responds to growing demand from the nation's largest and most innovative employers for educational benefits, from employee upskilling to student loan repayment. Bright Horizons' recent acquisition of GP Strategies' Tuition Program Management services business makes Bright Horizons the exclusive provider of tuition program management for GP Strategies' client base, allowing client employees access to personalized resources that help to streamline the outside education process and enhance the employee experience. These clients include some of the world's most reputable and leading employers, such as United Technologies and AMD. Additionally, GP Strategies and Bright Horizons have partnered to extend referrals to each other's clients to enhance client access to service offerings provided by both Bright Horizons and GP Strategies.

16:18 EDT Gulfport Energy backs FY19 capital budget and production guidance - Gulfport reaffirms its expectation that 2019 total capital expenditures will range between $565M-$600M after adjusting for the planned divestiture of certain non-operated assets. With this level of capital spend, Gulfport continues to forecast its 2019 average daily net production will range between 1,360 MMcfe to 1,400 MMcfe per day. Based on actual results during the nine-month period ended September 30, 2019, and utilizing current strip pricing at regional pricing points the company sells its products, Gulfport reiterates its expected 2019 natural gas and oil differential guidance. Gulfport now forecasts its expected 2019 realized NGL price, before the effect of hedges and including transportation expense, to be approximately 35% of WTI .

16:16 EDT Funko jumps 4%, or 75c, to $18.75 after Q3 tops estimates

16:13 EDT Concho Resources recommends shareholders reject mini-tender offer by TRC Capital - Concho Resources announced that it received notice of an unsolicited "mini-tender" offer by TRC Capital Investment Corporation to purchase up to 2M shares of Concho common stock at a price of $62.85 per share in cash. TRC Capital's offer price is approximately 4.51% lower than the $65.82 closing share price of Concho's common stock on October 25, 2019, the last trading day before the offer was commenced. The offer is for approximately 0.99% of the Company's common shares outstanding.

16:13 EDT Bluebird expects to treat the first Zynteglo commercial patient in early 2020 - The company said, "In October, bluebird bio announced that the European Medicines Agency approved the refined commercial drug product manufacturing specifications for ZYNTEGLO, a one-time gene therapy for patients 12 years and older with transfusion-dependent beta-thalassemia who do not have a beta0/beta0 genotype, for whom hematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen-matched related HSC donor is not available. With this update, apceth is in the final stages of preparing to manufacture ZYNTEGLO for commercial use. The company continues to proceed with discussions on value-based payment agreements and Qualified Treatment Center contracts and expects to treat the first commercial patient in early 2020."

16:11 EDT B&G Foods continues to believes shares are undervalued - The company said, "Finally, we continue to believe our stock is undervalued and repurchased 1.3 million shares of common stock in the third quarter at an average price of $18.55, or $24.7 million in the aggregate."

16:08 EDT Landec appoints Dawn Kimball as Chief People Officer - Landec Corporation announced Dawn Kimball as senior VP and Chief People Officer. She will lead the human resources organization and serve as a steward of Landec's culture. Kimball returns to Landec after previously serving as senior VP of human resources. Prior to rejoining Landec, Kimball served as VP, enterprise learning and talent management at Charles Schwab & Co., and as director of human resources while at Belcorp USA.

16:06 EDT Pinterest reports Q3 MAUs up 28% from last year to 322M - Reports Q3 ARPU global 90c vs. 79c last year. "In the third quarter, revenue grew 47% year over year and MAUs grew 28% to 322 million. We saw double-digit user growth in nearly all international countries," said Todd Morgenfeld, Pinterest CFO. "We are thrilled to serve Pinterest ads in 28 markets currently, compared to seven at the end of 2018. Pinterest also realized adjusted EBITDA profitability in Q3."

16:03 EDT Qorvo announces $1B share repurchase program - Qorvo announced that its board has authorized the repurchase of up to $1B of the company's outstanding common stock. The new repurchase program includes approximately $117M authorized under a prior program.

16:00 EDT BeiGene trading halted, news dissemination

15:33 EDT U.S. Steel completes strategic investment in Big River Steel - United States Steel Corporation announced that it has completed its acquisition of a 49.9% ownership interest in Big River Steel for approximately $700M, which implies an enterprise value of $2.325B. The financial impact of this acquisition will begin to be reflected in U. S. Steel's Q4 results. As announced on October 1, 2019, the transaction includes a call option that gives U. S. Steel the right to acquire the remaining 50.1% of Big River within four years at an agreed-upon price formula. Until that time Big River will operate independently.

15:07 EDT ClubCorp acquires seven golf and country clubs from Toll Brothers division - ClubCorp announces it has acquired seven golf clubs in residential communities located on the East Coast from Toll Golf, the golf and country club division of Toll Brothers. "As a leader in the industry, ClubCorp brings the highest standards of operations and an ever-expanding network of reciprocal privileges and products. This is the best fit for these clubs moving forward and a highly advantageous move for the members, whom I know will enjoy their new benefits," said Douglas Yearley, Jr., Chairman and COO of Toll Brothers.

14:51 EDT Spotify launches standalone app 'specifically' for kids and families - The streaming music service announced earlier "it decided to launch a fun standalone app designed with safety in mind specifically for kids and families." "Spotify Kids was born out of the desire to create a playground of sound just for kids-to build a place where younger kids can explore their favorite music and stories in a fun environment. The content is ad-free and hand-picked by a team of editors, and the experience is bursting with color. Our visuals help guide young minds through the app with simple navigation and scaled-back text. Before setting out to explore, each kid can also select a custom avatar and color theme to personalize their experience," said Alex Norstrom, Spotify's Chief Premium Business Officer. Reference Link

14:04 EDT Newmont Goldcorp says Quecher Main project achieves commercial production - Newmont Goldcorp announced that the Quecher Main project at Yanacocha in Peru achieved commercial production safely, ahead of schedule and under budget. The full project, including future leach pad expansions, is expected to be completed for approximately $275M of development capital which is below the company's initial estimate. Quecher Main extends the life of the Yanacocha operation to 2027, contributing average annual gold production of approximately 200,000 ounces from 2020 through 2024 at all-in sustaining costs between $900 and $1,000. The project is expected to generate an internal rate of return of approximately 15% at a $1,200 gold price. "Quecher Main is the fourth profitable project we've brought into operation on four different continents this year, on schedule and within budget," said Tom Palmer, President and CEO. "The project takes advantage of Yanacocha's existing infrastructure to add profitable production from remaining oxide ores while also serving as a bridge to future growth opportunities, including Yanacocha's extensive sulfide deposits."

13:25 EDT Amazon says new AWS Spain Region will arrive in next several years - Amazon Web Services, an Amazon.com company, announced it will open an infrastructure region in Spain. The new AWS Europe (Spain) Region will consist of three Availability Zones at launch, and will be AWS's seventh region in Europe, joining existing regions in Dublin, Frankfurt, London, Paris, Stockholm, and the upcoming Milan region launching in early 2020. The Spain Region is expected to open late 2022 or early 2023. Currently, AWS provides 69 Availability Zones across 22 infrastructure regions worldwide. With this announcement, AWS now has announced plans for 13 more Availability Zones and four more Regions in Indonesia, Italy, South Africa, and Spain, the company noted.

13:03 EDT L.B. Foster secures multiple infrastructure construction projects - L.B. Foster Company announced that it has secured several orders for infrastructure construction and capital improvement programs worth $40M. The company's Protective Coatings business, which coats steel line pipe for midstream oil and gas transmission lines from its Birmingham, AL facility, is participating in a major construction project to coat approximately 2.5M feet of 24-inch pipe. In the Rail and Construction segments, the company has secured several orders for crucial passenger transit and short line capital improvement and expansion projects. The company also reported it had been awarded additional work from the same engineering and construction firm that it worked with on the large $28M Port Everglades project booked last year in Q3.

13:01 EDT Applied DNA Sciences to effect 1-for-40 reverse split - Applied DNA Sciences announced that it will effect a 1-for-40 reverse split of its outstanding common stock effective at on Friday, November 1. The company's common stock will begin trading on a split-adjusted basis when The Nasdaq Capital Market opens on Friday, November 1 under the existing symbol "APDN."

12:37 EDT Atento appoints Gustavo Tasner as COO - Atento announced the appointment of Gustavo Tasner as COO and a member of the executive committee, effective November 1. Before joining Atento, Tasner served 14 years at Capgemini, where held positions such as Head of Business Services Operations for the Americas overseeing ten delivery centers in the US, Canada, Brazil and Guatemala and servicing 22 countries.

12:18 EDT Arrowhead presents preclinical data on ARO-ENaC at NACFC - Arrowhead Pharmaceuticals presented preclinical data at the 2019 North American Cystic Fibrosis Conference on ARO-ENaC, an inhaled RNAi therapeutic being developed as a potential treatment for cystic fibrosis, which is a rare disease caused by genetic mutations that lead to mucus buildup in the lungs and pancreas. Arrowhead is currently conducting IND/CTA-enabling studies to support regulatory filings in the first half of 2020 for first-in-human studies. Bruce Given, M.D., COO and head of R&D at Arrowhead, said: "We view the epithelial sodium channel, ENaC, as an exciting target in the treatment of CF and one that is well suited to an RNAi-based intervention. Based on its mechanism of action, ARO-ENaC has the potential to provide clinical benefit to all patients with CF, regardless of genotype, and may prove useful in combination with existing or new CFTR-targeted therapies. The data presented today show that ARO-ENaC can accelerate mucociliary clearance in normal sheep and also preserve airway physiology in a sheep disease model of impaired mucociliary clearance. In addition, animal models indicate that ARO-ENaC can reduce ENaC activity in the lung but avoid impact in the kidney, which has historically been a key safety liability for prior investigational small molecule ENaC inhibitors." Key points presented at NACFC 2019 include the following: Arrowhead's pulmonary epithelial TRiM-enabled delivery platform increased potency of RNAi triggemediated silencing of alphaENaC mRNA, and durably reduced whole lung gene expression in rodents; In normal sheep, inhaled ARO-ENaC produced dose-dependent acceleration of mucociliary clearance, which is a lung physiology endpoint linked to pulmonary function in patients with CF; Inhaled ARO ENaC preserves lung clearance in a sheep disease model of mucostasis ARO-ENaC may offer a new renal-sparing, genotype-agnostic therapy for all patients with CF, and exhibiting the potential for an extended duration of action that should minimize treatment burden.

12:09 EDT Psychemedics responds to court decision - Psychemedics Corporation issued a response to a Massachusetts Supreme Judicial Court ruling in the case of Boston Police Department v. The Massachusetts Civil Service Commission, which dealt with the Boston Police Department's 2012 decision not to hire an applicant after the applicant failed a Psychemedics Hair Test. Previously, a Massachusetts Superior Court Judge had found that the Boston Police Department's reliance on the test was proper. The Massachusetts Supreme Judicial Court overturned the Superior Court's decision, citing as one of its grounds the applicant's "ardent" denials of drug use during his testimony before the Massachusetts Civil Service Commission, or CSC, but also acknowledging that it could not consider "facts and studies" that the court found were not before the CSC. In a 31-page dissenting opinion, however, Supreme Court Justice Kafker disagreed, citing several studies which have "established the high degree of reliability of the testing procedures at issue." The court took no position on the degree of accuracy of the Psychemedics Hair Test. "We respectfully but strongly disagree with this result, particularly as it involves a critical public safety issue," said Psychemedics CEO Raymond Kubacki "The people of Boston deserve now more than ever to have armed police officers who are not under the influence of drugs. As recognized by Justice Kafker, the Court and the CSC relied on outdated and flawed studies that did not employ the multitude of protections that Psychemedics has used on every single one of its tests for the past 30 years and did not have the benefit of the most recent studies that have demonstrated the effectiveness of these protections. As just one example, as recently as 2014, the Federal Bureau of Investigations has unequivocally stated that these protections protect police officers by effectively eliminating false-positive results."

12:05 EDT Dine Brands partners with Postmates for Applebee's, IHOP deliveries - Postmates announced that is has partnered with Dine Brands. Postmates customers can now order from both of these restaurants in the more than 3,500 cities that the company operates in. From the outset of the partnership, Postmates and Dine Brands will integrate delivery orders directly into Applebee's and IHOP's Point of Sale systems, respectively, which will streamline the order fulfillment process.

12:00 EDT Wayfair falls -17.1% - Wayfair is down -17.1%, or -$17.27 to $83.81.

12:00 EDT California Resources falls -20.8% - California Resources is down -20.8%, or -$1.26 to $4.79.

12:00 EDT Murphy USA rises 15.6% - Murphy USA is up 15.6%, or $14.83 to $109.67.

11:42 EDT Turkcell trading resumes

11:26 EDT CyrusOne says not currently pursuing sale of the company - On its Q3 earnings conference call, CyrusOne said that it is not currently pursuing a sale of the company and does not intend to have any further comments on recent media reports and market rumors.

11:15 EDT CyrusOne trading halted, volatility trading pause

10:54 EDT Adtran says biggest customer CenturyLink had 'great quarter' with us

10:16 EDT Hemp, Inc. announces support of USDA proposed hemp rules - Hemp announced its support of the White House's approval of plans to regulate hemp and its derivatives, signing off on interim final rules for the crop that were submitted by the U.S. Department of Agriculture. In addition to Hemp, Inc.'s 85,000 square-foot multipurpose industrial hemp processing facility in Spring Hope, North Carolina, the Company operates processing center in Medford, Oregon, and a 500-acre hemp growing Eco-Village in Golden Valley, Arizona. The Company will be launching KING OF HEMP pre-rolls later this year; this is one of the first trademark registrations to issue in the PTO's post-Farm Bill era of allowing trademark registrations on products containing less than .3 percent THC and the first trademark registration for "hemp cigarettes." "We have come such a long way since the decades-long ban on hemp. From lifting the ban, to the first harvest in 80 years, we are getting closer to receiving clarity on an array of hemp-specific policies such as safety and quality control standards, so this will be a game-changer for the industry," said Hemp CEO Bruce Perlowin. "This is going to be great for growers, especially small farmers. They'll benefit from the expansion of crop insurance, standards and infrastructure that can be built out based on the sheer certainty that comes with uniform regulations." The details of this plan have not yet been disclosed, however they are expected to provide clarity on an array of hemp-specific policies ranging from THC potency testing guidelines, banking, and quality control standards.

10:12 EDT Horizon Therapeutics announces integrated data from trials of teprotumumab - Horizon Therapeutics announced integrated, pooled efficacy data from the Phase 2 and Phase 3 clinical trials of teprotumumab for the treatment of active thyroid eye disease ompared to placebo. The results support prior analyses of significant reductions in inflammation, proptosis and diplopia, as well as improvements in quality of life. These data were presented at the 89th Annual Meeting of the American Thyroid Association. This is the first presentation of the pooled analyses and builds on the individual positive results of the Phase 2 and Phase 3 clinical studies. Teprotumumab is an investigational medicine and its safety and efficacy have not been established. The teprotumumab Biologics License Application was granted Priority Review by the U.S. Food and Drug Administration and if approved, teprotumumab would be the first FDA-approved medicine for the treatment of active TED. The Prescription Drug User Fee Act goal date is March 8, 2020. The pooled analysis of the Phase 2 and Phase 3 OPTIC studies presented during ATA represent the experience of 171 patients with recent onset of TED treated with teprotumumab or placebo every three weeks for a total of eight infusions. Key study findings include the following: Proptosis: At Week 24, 77.4% of patients receiving teprotumumab experienced a greater than or equal to2 mm reduction in proptosis, compared to 14.9% of patients receiving placebo. The reduction in average change from baseline through Week 24 in proptosis was greater in patients who received teprotumumab than in those who received placebo. Diplopia: The diplopia responder rate, which is defined as the percentage of patients whose diplopia improved 1 or more grades, was higher with teprotumumab versus placebo in those with baseline diplopia. Quality of Life: Patients treated with teprotumumab experienced improvements in average change from baseline through week 24 in QoL scores, including visual functioning and appearance. The GO-QoL scale consists of two subscales to evaluate the quality of life of patients with TED, including impacts on visual function and self-assessment of appearance. A change of 6 points is considered clinically significant. Clinical Activity Score: At Week 24, nearly two-thirds of teprotumumab-treated patients had no or minimal inflammatory symptoms as measured by CAS compared to 21.8% of placebo-treated patients. CAS is a scale used to assess the disease activity of TED, and measures the degree of inflammation, including pain, swelling and redness. The CAS scale ranges from 0 to 7, with a score of 0 representing no signs or symptoms of inflammation. In addition, 73.8% of teprotumumab patients versus 13.8% of placebo patients had an overall response at Week 24 - defined as the percent of patients with greater than or equal to 2-point reduction in CAS and greater than or equal to 2 mm reduction in proptosis from baseline. As previously reported, the majority of adverse events experienced with teprotumumab treatment were graded as mild to moderate and were managed in the trials, with few discontinuations. In the Phase 2 clinical study, the only drug-related adverse event identified by the investigators was hyperglycemia. Other adverse events included nausea, diarrhea, muscle spasms, hearing impairment and inflammatory bowel disease in a patient with a recent diagnosis of ileitis and colitis. No deaths occurred during the trial. The safety profile of teprotumumab in the Phase 3 clinical study was similar to that seen in the Phase 2 study with no new safety observations.

10:01 EDT CACI wins $907M U.S. Army task order - CACI announced that it has been awarded a five-year task order, with a ceiling value of nearly $907M for new and continuing work, on a U.S. Army Intelligence and Security Command Global Intelligence Support Service contract task order to protect U.S. forces in Afghanistan by providing intelligence operations and analytic support. Under the task order, CACI intelligence and counterintelligence experts will continue to provide mission expertise in intelligence operations and analytic support from locations both within the United States and abroad to support U.S. operations in Afghanistan.

10:00 EDT Wayfair falls -15.5% - Wayfair is down -15.5%, or -$15.71 to $85.37.

10:00 EDT Orion Group rises 16.8% - Orion Group is up 16.8%, or 74c to $5.14.

10:00 EDT Murphy USA rises 17.7% - Murphy USA is up 17.7%, or $16.81 to $111.65.

09:47 EDT WWE falls -13.2% - WWE is down -13.2%, or -$8.80 to $57.64.

09:47 EDT Newpark Resources falls -24.1% - Newpark Resources is down -24.1%, or -$1.70 to $5.34.

09:47 EDT Murphy USA rises 15.8% - Murphy USA is up 15.8%, or $14.95 to $109.79.

09:25 EDT Embraer delivers 17 commercial, 27 executive jets in Q3 - Embraer delivered a total of 44 jets in the third quarter, of which 17 were commercial aircraft and 27 were executive jets (15 light and 12 large). As of September 30th, the firm order backlog totaled $16.2B.

09:19 EDT RingCentral, Avaya announce closing, details of strategic partnership - RingCentral (RNG) and Avaya (AVYA) announced the closing of their previously announced strategic partnership. Avaya and RingCentral will introduce a new solution, Avaya Cloud Office by RingCentral, which will be the exclusive public unified communications as a service solution marketed and sold by Avaya. Avaya Cloud Office combines RingCentral's UCaaS platform with Avaya's technology, services and migration capabilities to create a differentiated UCaaS offering. The companies expect to launch Avaya Cloud Office in Q1 of calendar 2020. RingCentral is contributing $500M to its partnership with Avaya, including a $125M investment of 3% redeemable preferred equity that is convertible at $16 per share and an advance of $375M primarily in stock for future payments and certain licensing rights.

09:11 EDT Garrison Capital shareholder Clear Harbor issues letter to Board - Garrison Capital stockholder Clear Harbor Asset Management, owning approximately 1.25% of the company's outstanding common stock, has delivered a letter to the Board of Directors expressing its concerns with the company's "persistent underperformance". Clear Harbor states that "despite considerable effort to work constructively with the company to address the concerns facing Garrison Capital, the Board has failed to take substantive steps to improve company performance and refuses to hold management accountable for its repeated failures". The letter states, among other things: "(...) Since 2015, book value per share has fallen from $13.98 to $10.30.(...) This abysmal performance is occurring in what is by nearly all measures a historically benign credit environment. (...) Furthermore, Garrison has not covered its dividend payments from operating income. (...) In the last 12 months, Garrison stock is down 4% on a total return basis while the index of US Investment Companies is up 11%. (...) the logical path for Garrison at this point is an orderly liquidation. We believe stockholders have suffered enough and deserve to at least recover the difference between the market price of the stock and liquidation value. We recommend that a new, highly qualified independent investment advisor with liquidation expertise be appointed to oversee this process. (...) we are highly skeptical that a strategic transaction for Garrison can provide greater stockholder value than an orderly liquidation. (...) We believe the Board's inaction and unwillingness to hold management and its external manager accountable for the Company's continued poor performance is a clear breach of the Board's fiduciary duties. Based on the Company's frustrating lack of response and meaningful action to date, we are evaluating all options to protect the interests of stockholders.(...)"

09:08 EDT Blue Apron sees FY19 adjusted EBITDA loss ($10M)-($7M)

09:03 EDT Nissan North America, Sirius XM extend agreement through 2028 model year - SiriusXM (SIRI) announced an agreement with Nissan North America (NSANY) that extends the ongoing relationship between the two companies through the 2028 model year. Nissan and INFINITI customers will continue to get a three-month introductory SiriusXM All Access subscription - SiriusXM's most expansive programming package which includes access to the SiriusXM mobile app - with the purchase of equipped vehicles. Within the term of this agreement extension Nissan and INFINITI vehicles will begin offering SiriusXM with 360L, SiriusXM's next generation of in-car audio entertainment. SiriusXM with 360L delivers content via both satellite and streaming, and provides an unparalleled entertainment experience by offering more than 200 live SiriusXM channels plus the ability to access on-demand programming from thousands of hours of varied SiriusXM content - including exclusive interviews, shows and live performances. SiriusXM with 360L provides more choice in entertainment to drivers and their passengers than ever before and enables them to enjoy a more personalized "lean back" experience as SiriusXM serves content recommendations based on their listening preferences. Customers purchasing properly equipped Nissan and INFINITI vehicles will also receive a three-month subscription to the SiriusXM Traffic and SiriusXM Travel Link infotainment services. SiriusXM Traffic helps drivers avoid congestion before they reach it with detailed information on traffic speed, accidents, construction, road closures and more. SiriusXM Travel Link delivers timely and helpful information to drivers and passengers including weather, fuel prices, available parking, sports scores, movie listings and stock prices. Customers who purchase Nissan and INFINITI Certified Pre-Owned vehicles will continue to receive a three-month introductory subscription to SiriusXM All Access.

08:47 EDT AbbVie says Rinvoq meets primary, secondary endpoints in Phase 3 PA study - AbbVie announced top-line data from the SELECT-PsA 2 Phase 3 study. In this study, both doses of RINVOQ met the primary endpoint of ACR20 response at week 12 versus placebo in adult patients with active psoriatic arthritis who have responded inadequately to one or more biologic disease modifying anti-rheumatic drugs. In addition, patients on both doses of RINVOQ achieved significantly greater responses compared to placebo for all ranked secondary endpoints.1 SELECT-PsA 2 is the first study evaluating the efficacy and safety of RINVOQ in adult patients with active psoriatic arthritis.1 RINVOQ, a selective and reversible JAK inhibitor discovered and developed by AbbVie, is being studied as a once-daily therapy in psoriatic arthritis and multiple immune-mediated diseases. Results show that at week 12, 57/64 percent of patients receiving 15/30 mg of RINVOQ achieved ACR20, respectively, compared to 24 percent in the placebo group. Additionally, ACR50 was achieved by 32/38 percent of patients receiving 15/30 mg of RINVOQ, respectively, compared to 5 percent on placebo at week 12. In this study, the safety profile of RINVOQ was consistent with that observed in previously reported studies in patients with rheumatoid arthritis, with no new safety risks detected.

08:43 EDT Wayfair sees Q4 revenue growth below current QTD performance, consensus $2.67B - Sees Q4 unutilized rent cost $15M-20M. Sees Q4 adjusted EBITDA margin down 7%-7.5%. Says well positioned for holiday season.

08:40 EDT Galmed presenting data on aramchol for NASH at AASLD meeting - Galmed will present new data at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases or AASLD in Boston, November 8-12. This new pre-clinical data elucidates the mechanism by which Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3/4 clinical trial for the treatment of nonalcoholic steatohepatitis or NASH, and fibrosis, affects glucose metabolism in the liver that resulted in a reduction of HbA1C in patients in the company's Phase IIb trial. The data suggests that Aramchol improves liver glucose homeostasis in patients and murine models. Galmed will also present clinical data on the rationale for the Phase 3/4 dose selection and its potential increased efficacy.

08:38 EDT Magal Security receives $2.4M in airport security contracts - Magal Security has won contracts amounting to $2.4M, supporting the critical perimeter security infrastructure of airports. Most of the awards were for two major international airports, but also includes products and services for several other airports globally. The majority of orders were for the maintenance related to previously purchased products and services from Magal.

08:36 EDT Envision Solar receives purchase order for solar powered EV chargers - Envision Solar International announced that The Lawrence Livermore National Laboratory has issued another purchase order to add to its existing fleet of EV ARC units. The Lawrence Livermore National Laboratory is a research and development institution for science and technology applied to national security. This third order from LLNL brings the total number of EV ARC units deployed at the Livermore location to five. The latest EV ARC units were delivered with integrated ChargePoint chargers for fleet vehicles.

08:34 EDT British American Tobacco selects Synchronoss Digital Experience Platform - Synchronoss Technologies announced that it is launching a multi-country pilot of the Synchronoss Digital Experience Platform for British American Tobacco. The Synchronoss DXP solution will provide BAT with a toolkit of capabilities that vastly simplifies IT delivery, giving BAT the capacity to quickly design, deploy, manage and optimize customer journeys while providing a unified experience across all its owned retail locations.

08:30 EDT Wayfair says expects advertising costs to drop due to repeat customer base - Say new warehouse will come online in 2020. Says there is approximately $600B total addressable market rapidly moving from brick and mortar to online. Says house brands are resonating with customers. Says expanding business in Canada, UK and Germany is a priority. Says gross margins were lower in Q3 than past few quarters due to tariff related pressures in the U.S. Comments taken from Q3 earnings conference call.

08:15 EDT Unity Biotechnology announces first patient dosed in Phase 2 study of UBX0101 - UNITY Biotechnology announced that the first patient has been dosed in a Phase 2 study of UBX0101 in patients with osteoarthritis of the knee. The Phase 2 study of UBX0101 in patients with painful, moderate-to-severe OA of the knee is expected to enroll approximately 180 patients. Initial 12-week results are expected in the second half of 2020. The study is a randomized, double-blind, placebo-controlled study evaluating three UBX0101 doses administered via a single intra-articular injection. The primary measure will be an assessment of knee pain at 12 weeks using the WOMAC-A instrument. Secondary measures will include safety and tolerability, pain and function at 12 weeks, as well as all of these endpoints at 24 weeks.

08:14 EDT CRA International increases quarterly dividend 15% to 23c per share - CRA International announced that its board has declared a 15% increase in the quarterly cash dividend to 23c per common share to be paid on December 13 to shareholders of record of CRA's common stock as of the close of business on November 26.

08:11 EDT Wesco down 1.5% after reporting Q3 results

08:10 EDT VirTra awarded patents for TASER training - VirTra, announced that the United States Patent and Trademark Office has issued the company two new patents: patent 10,438,503, which relates to VirTra's TASER cartridge kits, and patent 10,436,539, which relates to mechanical malfunction of real firearms used in simulation training. Based on the parameters of patent 10,438,503, VirTra is the only company in the United States that can produce or sell a specially triggered training cartridge for the TASER line of products by Axon, the global leader in connected public safety technologies. The patent covers VirTra's proprietary method of reliably triggering the training device based on the unique acoustic sound produced by a TASER Conducted Energy Weapon's electrical arc. This innovation allows trainees to deploy the cartridges from a real TASER CEW during simulation training and avoid high-voltage feedback. It also allows trainees to practice with a TASER CEW's "ARC" and/or "Re-ARC" functions, which increases the realism of each training session. By using a live CEW while training in VirTra's simulators, trainees are able to improve their technique and develop proper habits that carry into real world situations. The patent applies to both legacy units and the latest multi-cartridge systems used for the TASER X2 and TASER 7 weapons.

08:05 EDT Great Panther Silver names Neil Hepworth as COO - Great Panther Silver is pleased to report the appointment of Neil Hepworth, Chartered Engineer, UK, as COO. Neil Hepworth is a Mining Engineer with over 30 years of experience in underground mining operations and technical and operational experience in open pit mines.

07:58 EDT Performance Shipping appoints Andreas Michalopoulos as deputy CEO - Performance Shipping announced that its board of directors has unanimously appointed Mr. Andreas Michalopoulos to the position of Deputy CEO, effective immediately. Mr. Michalopoulos, who is presently the Company's CFO and Treasurer, will retain such position for the time being. While it is expected that Mr. Michalopoulos will eventually succeed Mr. Symeon Palios as CEO, Mr. Palios' active role as CEO and Chairman of the Company will be unchanged in the near term.

07:54 EDT Recro Pharma granted appeal for IV Meloxicam NDA - Recro Pharma announced that it has received a written decision from the U.S. Food and Drug Administration granting its appeal of the Complete Response Letter relating to the New Drug Application seeking approval for intravenous meloxicam. The FDA's letter states that the appeal was granted "specific to the request...that the NDA provides sufficient evidence of effectiveness and safety to support approval." The letter also states that "before IV meloxicam can be approved and legally marketed, agreed-upon labeling must be negotiated with the Division." The Company is now in the process of preparing a comprehensive response to the FDA that includes proposed labeling that aligns with the FDA guidance received in the written decision letter and provides the relevant evidence from the filed NDA to ensure safe and effective use of IV meloxicam by prescribers. The Company continues to expect that the spin out of the Recro Pharma Acute Care segment into an independently traded company will proceed as planned, and is expected to be concluded during the fourth quarter of 2019.

07:51 EDT Antares Pharma receives final payment from sale of ZOMAJET - Antares Pharma announced that it has received the final payment of $2.5M from Ferring Pharmaceuticals in connection with the previously disclosed sale of Antares' worldwide rights, including certain fixed assets, for the ZOMAJET needle-free auto injector device to Ferring. Antares had been the worldwide supplier of ZOMAJET devices to Ferring and JCR Pharmaceutical Company Ltd. With the final payment received, the Company will no longer manufacture and supply the devices. The gain on the sale of the needle free product line was previously recorded in the fourth quarter of 2018.

07:49 EDT Global Payments announces strategic partnership with Desjardins in Canada - Global Payments announced an agreement with Desjardins Group to acquire its existing merchant acquiring business and portfolio of approximately 40,000 merchants. As part of the transaction, Global Payments will enter into an exclusive 10-year marketing alliance agreement under which Desjardins will refer members to Global Payments for payment technology and acquiring solutions. The transaction is expected to close by early 2020, subject to receipt of regulatory approvals and satisfaction of customary closing conditions.

07:45 EDT AirNet Technology regains Nasdaq compliance - AirNet Technology announced that based on a notification letter recently received from the Listing Qualifications Department of The Nasdaq Stock Market, the company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules.

07:42 EDT Oncolytics provides update on partners phase 3 clinical trial for pelareorep - Oncolytics (ONCY) provided an update on its partner, Adlai Nortye's, clinical progress and approval by the National Medical Products Administration, or NMPA, of China for initiating a phase 3 clinical trial for pelareorep. The phase 3 study, initially based on positive results from the randomized phase 2 metastatic breast cancer study IND-213, will be finalized based on data from Oncolytics' AWARE-1 breast cancer study in combination with Roche's (RHHBY) Tecentriq and BRACELET-1 metastatic breast cancer study in combination with Pfizer's (PFE) and Merck's (MRK) Bavencio. These studies provide valuable biomarker data that will help define enrollment criteria to include patients most likely to respond to treatment with pelareorep and increase the likelihood of a positive clinical outcome in this important phase 3 registrational study. Oncolytics and Adlai Nortye entered into an $86.6M regional licensing agreement in November 2017, providing Adlai with exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea and Taiwan. To date Oncolytics has received $5M in up front payments and is eligible for $81.6M in milestone payments.

07:38 EDT Aldeyra announces results from allergen chamber clinical methods trial - Aldeyra announced expanded results from the company's allergen chamber clinical methods trial of topical ocular reproxalap in patients with allergic conjunctivitis, and Phase 3 clinical trial plans based on recent feedback from the FDA. The double-masked, randomized, vehicle-controlled, crossover allergen chamber clinical methods trial assessed the efficacy and safety of 0.25% and 0.5% concentrations of reproxalap topical ophthalmic solution compared with vehicle in 70 patients with ocular allergy to ragweed. Patient-reported ocular itching and tearing, and investigator-assessed ocular redness, were recorded at various intervals over approximately 3.5 hours during exposure to a standardized amount of ragweed pollen. Test article was administered before chamber entry and at 90 minutes post-entry, near the peak of allergy symptoms and signs. Relative to patients treated with vehicle, patients treated with 0.25% or 0.5% reproxalap demonstrated statistically significant reduction in ocular itching, redness and tearing. The total ocular symptom score, a combination of itching, redness, and tearing, was also significantly lower in reproxalap-treated subjects than in vehicle-treated subjects. Consistent with the positive results from the Alleviate Phase 3 clinical trial in allergic conjunctivitis released earlier this year, there was no statistical difference between the activity of 0.25% and 0.5% reproxalap. Consistent with all prior clinical experience with topical ocular reproxalap in over 1,000 patients across 12 clinical trials, there were no observed safety or tolerability concerns, and the most common treatment-emergent adverse event was transient instillation site irritation.

07:36 EDT Houghton Mifflin sees 2019 CapEx $150M-$160M

07:34 EDT Bausch Health announces issuance of Xifaxan patent from USPTO - Bausch Health and its gastroenterology business, Salix Pharmaceuticals announced that the U.S. Patent and Trademark Office, or USPTO, has issued an additional patent covering the use of Xifaxan 550 mg tablets to treat symptoms of Irritable Bowel Syndrome, or IBS. The patent issued is United States Patent No. 10,456,384. Final expiry of the new patent covering IBS is in February 2029. Xifaxan is now protected by 23 patents covering the composition of matter and the use of Xifaxan listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book.

07:30 EDT Castle Biosciences presents results from DecisionDx-Melanoma test study - Castle Biosciences announced the presentation of results from a study validating a newly developed nomogram tool that combines information from the DecisionDx-Melanoma test with clinicopathologic features to improve prediction of patients' risk of melanoma recurrence. The study included a prospective cohort of 1,124 patients with melanoma from nine dermatology centers participating in the Cutaneous Oncology Research Consortium, or CORC. Those with at least one year of follow-up or a recurrence event who also had complete clinicopathologic information and a DecisionDx-Melanoma result available were included in the nomogram development. The median follow-up time of this cohort was 3.0 years and median age was 67 years. The majority of patients had thin melanoma and ulceration was present in 7% of patients. The DecisionDx-Melanoma prognostic test for cutaneous melanoma predicts 5-year risk of recurrence and metastasis as low risk or high risk. Patients with Class 1A DecisionDx-Melanoma test results had significantly better recurrence-free survival, or RFS, at 1.5 years compared to patients with Class 2B results. Similar results were seen for distant metastasis-free survival, or DMFS, with 99.6% survival for patients with a Class 1A result and 84.4% for those with a Class 2B result. In a multivariate Cox regression model including DecisionDx-Melanoma and clinical features, only Breslow thickness and DecisionDx-Melanoma results were significant predictors for RFS. Researchers developed an optimized nomogram that includes American Joint Committee on Cancer T category and DecisionDx-Melanoma test results as the strongest variables contributing prognostic information. The nomogram was then independently validated for prediction of recurrence in a retrospective cohort of 901 patients who had a median follow-up of 5.8 years. Using clinical and molecular variables, the validated nomogram improved recurrence risk prediction beyond clinicopathologic factors alone.

07:30 EDT LKQ Corp. increases share repurchase authorization by $500M - LKQ Corporatio announced that its board has authorized a $500M increase and a one year extension to its stock repurchase program, raising the aggregate authorization under the program to $1 billion and authorizing repurchases through October 25, 2022. Since the company implemented the stock repurchase program in October 2018, the company has repurchased approximately 13.2 million shares of the company's common stock for approximately $352 million. At September 30, 2019, the company had 306 million shares of common stock outstanding.

07:29 EDT KBR awarded $45M contract by U.S. Army Contracting Command - KBR announced it has been awarded a one-year $45M contract modification by the U.S. Army Contracting Command. KBR will continue to provide maintenance, supply, transportation and other logistics functions for the U.S. Army Prepositioned Stock-3 Charleston Afloat Program. This hybrid firm fixed price, cost-plus-fixed-fee contract extends work on the original contract until August 2020. This is the fourth option year on the contract, which was originally awarded in August 2015. Under this contract, KBR will provide Care of Supplies in Storage, or COSIS, and integrated logistics support. This support will include inventory management and control, serialization, storage, tactical vehicle maintenance, marking and labeling, and distribution at U. S. Army Field Support Battalion - Charleston in Goose Creek, South Carolina. KBR will also receive, inventory, and package various supply class stocks for storage. The company will perform maintenance on Army equipment that is prepositioned ashore and COSIS on ships afloat in the Indian and Pacific Oceans.

07:27 EDT Lantronix announces definitive agreement to acquire Intrinsyc Technologies - Lantronix announced that it has entered into a definitive arrangement agreement to acquire all of the outstanding shares of Intrinsyc Technologies Corporation. The transaction, which is subject to approval by the shareholders of Intrinsyc along with other specified closing conditions, has been unanimously approved by the board of directors of both companies and is expected to be completed by the end of this calendar year or shortly thereafter. Under the terms of the arrangement agreement, Lantronix will pay $0.55 and issue 0.2135 of a share of the common stock of Lantronix for each issued and outstanding share of Intrinsyc. Lantronix will, in the aggregate, pay approximately $11.5M in cash and issue approximately 4.3 million shares of its common stock to Intrinsyc shareholders. Following the transaction, Intrinsyc shareholders are expected to own approximately 16% of the outstanding shares of the common stock of Lantronix. Certain shareholders of Intrinsyc that collectively own approximately 14.5% of the outstanding shares of Intrinsyc have already entered into voting agreements to vote in favor of the transaction. The transaction will bring immediate scale to Lantronix, adding complementary IoT computing and embedded product development capabilities and expanding the company's IoT market opportunity. Lantronix sees significant operating and product development synergies in the combined company and expects the acquisition will be accretive in the first full quarter of operations. Lantronix affirms the guidance provided on September 10, 2019 for the quarter ended September 30, 2019. Net revenue is expected to come in above the mid-point of our guidance. Non-GAAP EPS is expected at the high end of our guidance. The company currently intends to announce these results on November 13, 2019.

07:24 EDT Crown Crafts announces special cash dividend of 25c per share - Crown Crafts announced that its Board of Directors has declared a special cash dividend on the company's Series A common stock of 25c per share, along with a quarterly cash dividend of 8c per share. Both dividends will be paid on January 3, 2020 to shareholders of record at the close of business on December 13.

07:22 EDT Macquarie Infrastructure intends to pursue strategic alternatives - Macquarie Infrastructure announced its intention to actively pursue strategic alternatives including a sale of the company or its operating businesses as a means of unlocking value for shareholders. Christopher Frost, MIC's chief executive officer, said, "Over the past 18 months we have successfully executed initiatives including the sales of smaller and non-core businesses which have strengthened our balance sheet and increased our financial flexibility. In addition, the investments we have made in the infrastructure of our businesses during this period have both improved their competitive position and increased their resilience.Building on the momentum created by these actions, we are confident that now is the appropriate time to consider sales of our remaining businesses in order to unlock additional value for our shareholders." MIC has not set a timetable for completing any sale or sales. The company notes that there can be no assurances as to the form and timing of any transaction as a result of this pursuit of strategic alternatives, or if any transactions will be consummated, and any final decisions remain subject to approval by the MIC board of directors. MIC does not intend to update the market on its progress unless or until it determines that further disclosure is appropriate or required by law. MIC has appointed Lazard as its lead financial advisor and White & Case as its legal counsel in connection with its pursuit of strategic alternatives.

07:20 EDT Can-Fite BioPharma announces results from Namodenoson End-of-Phase 2 meeting - Can-Fite BioPharma announced it has concluded an End-of-Phase 2 meeting with the FDA regarding its recently completed Phase II study of Namodenoson in the treatment of hepatocellular cancer, or HCC, the most common form of liver cancer. The purpose of the meeting was to review the Phase II study data with the FDA and to present Can-Fite's proposed Phase III study design to the regulatory agency. The FDA agreed with Can-Fite's proposed pivotal Phase III trial design to support a new drug application, or NDA, submission and approval. The Phase III study will enroll patients with advanced HCC, with underlying Child Pugh B7, or CPB7, cirrhosis, whose cancer has progressed on first line therapy. This design leverages the previously announced Phase II trial data, which showed promising efficacy signals in this population. The FDA's guidance will be incorporated into the Phase III study's final protocol.

07:17 EDT Sirius XM reports Q3 adjusted EBITDA up 12% to $657M - Adjusted EBITDA grew 12% to $657M in the third quarter and resulted in an adjusted EBITDA margin of 32.6%, growing approximately 160 basis points from 31.0% in the third quarter 2018. The adjusted EBITDA margin in the quarter was driven primarily by revenue growth across the business and cost efficiencies in subscriber acquisition costs and revenue share and royalties. "SiriusXM's robust third quarter saw strong results across the board. Total net additions benefited from continuing strength in the auto sector, and our adjusted EBITDA hit an all-time quarterly record of $657 million. Things have never been more exciting at the company as we continue to invest in our brands, content, products and expanded OEM distribution. With two months left in the year, we are raising 2019 guidance for revenue, adjusted EBITDA and free cash flow and we are confident in our expectations for self-pay subscriber growth," said Jim Meyer, CEO, SiriusXM. "We officially opened our new Hollywood studio complex with a special series of shows by Howard Stern. Howard is at the top of his game and was welcomed to LA by an array of stars and special live performances by Adam Levine and Green Day, all from our state-of-the-art street level performance space we call The Garage. Howard's broadcast followed a month of special shows, interviews, and performances in LA exclusively for us by Carrie Underwood, Julia Roberts, Dave Matthews and breakout artist Billie Eilish, to name a few. Re-establishing ourselves in the Entertainment Capital of the world, and being closer to compelling talent and brands, bolsters the value of our programming for our subscribers," added Meyer.

07:13 EDT Sirius XM raises FY19 guidance - "The company is increasing its guidance for pro forma revenue, adjusted EBITDA and free cash flow and reiterating existing full-year 2019 guidance for SiriusXM self-pay net subscriber additions. The company's increased full-year guidance for the combined company, including Pandora, is as follows: SiriusXM self-pay net subscriber additions approaching 1 million, Pro forma revenue of approximately $7.85 billion, Adjusted EBITDA approaching $2.4 billion, and Free cash flow of approximately $1.625 billion."

07:08 EDT Cesca Therapeutics to change name to ThermoGenesis, to change symbol to (THMO) - Cesca Therapeutics (KOOL) announced that the company will change its name to ThermoGenesis in order to better reflect its new strategic focus on becoming a key solution provider for cell manufacturing tools and services in the cell and gene therapy markets. In conjunction with the name change, the company will begin trading under the new Nasdaq ticker symbol, (THMO), effective Friday, November 1. In addition, the company's common stock will trade under a new CUSIP number, 88362L100, beginning on Friday, November 1.

07:06 EDT Agios Pharmaceuticals sees cash, cash equivalents sufficient through end of 2020 - Cash, cash equivalents and marketable securities as of September 30, 2019 were $540.5 million compared to $805.4 million as of December 31, 2018. The net decrease of $264.9 million in cash position was primarily driven by net expenditures to fund operations. The company expects that its cash, cash equivalents and marketable securities as of September 30, 2019, together with anticipated product and royalty revenue, anticipated interest income, and anticipated expense reimbursements under our collaboration and license agreements, but excluding any additional program-specific milestone payments, will enable the company to fund its anticipated operating expenses and capital expenditure requirements through at least the end of 2020.

07:04 EDT EQT Corporation sees 2020 total sales volume 1,450-1,500 Bcfe - Sees 2020 Capital expenditures of $1.30B-$1.40B, a $525M year-over-year reduction, compared to prior 2019 guidance.

07:00 EDT Encana to establish domicile in U.S., to rebrand to Ovintiv - Encana announced its intention to establish corporate domicile in the United States. The move, which requires shareholder, stock exchange and court approval, is expected to occur in early 2020. As part of this process, the new company will rebrand under the name Ovintiv. A special meeting of Encana shareholders will be held in early 2020 to approve the name change, the share consolidation and the U.S. domicile. Approval by two-thirds of votes cast will be required to approve the changes, as well as stock exchange and Canadian court approvals. A preliminary proxy statement/prospectus is expected to be filed with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities in early November. Following completion of the corporate redomicile and the adoption of its new name, the new company will begin trading on both the New York and Toronto stock exchanges under the ticker symbol (OVV)"

06:55 EDT Lantronix trading halted, news pending

06:52 EDT Spirit AeroSystems to acquire select assets of Bombardier aerostructures - Spirit AeroSystems Holdings (SPR) announced it has entered into a definitive agreement to acquire select assets of Bombardier (BDRBF) aerostructures and aftermarket services businesses in Belfast, Northern Ireland, known as Short Brothers; Casablanca, Morocco; and Dallas, United States, for cash consideration of $500 million. In addition, Spirit AeroSystems will assume approximately $300 million in net pension liabilities, and approximately $290 million of government grant repayment obligations, for a total enterprise valuation of $1,090 million, which equals 10 times the 2019 estimated Adjusted EBITDA of the acquired business. At closing, Spirit AeroSystems will pay $500 million to Bombardier and will make a cash contribution of approximately $130 million towards the pension liability, for total cash at closing of $630 million. The expected revenues of the acquired Bombardier operations will be approximately $1 billion in 2019. The transaction, which is expected to close in the first half of 2020, is subject to regulatory approvals and customary closing conditions. Spirit AeroSystems expects to realize approximately $60 million in synergies from the acquisition, which values the acquisition on a post-synergy EV / EBITDA multiple of 6.5x.

06:51 EDT PBF Logistics increases quarterly distribution to 52c per unit - The board of directors of PBF Logistics GP LLC, the Partnership's general partner, declared a regular quarterly cash distribution of 52c per common unit. The distribution is payable on November 26, 2019, to unitholders of record at the close of business on November 14, 2019.

06:49 EDT Tempur Sealy raises FY19 adj. EBITDA view to $485M-$500M - Tempur Sealy raised its financial guidance for 2019. For the full year 2019, the company currently expects adjusted EBITDA to range from $485 million to $500 million, raising the mid-point by $28 million. This increase of the mid-point is driven by the above-expectations performance of the North America business during the third quarter and the more favorable outlook in timing for the company's launch and channel fill with Mattress Firm, partially offset by the increases to variable compensation. At the mid-point, this would represent growth of 16% versus the reported full year 2018 adjusted EBITDA.

06:43 EDT Dicerna enters pact with Roche to develop DCR-HBVS - Dicerna (DRNA) announced a research collaboration and licensing agreement with Roche (RHHBY) to develop novel therapies for the treatment of chronic hepatitis B virus infection using Dicerna's proprietary GalXC RNAi platform technology. The collaboration will focus on worldwide development and commercialization of DCR-HBVS, Dicerna's investigational therapy in Phase 1 clinical development. The collaboration also includes the discovery and development of therapies targeting multiple additional human and viral genes associated with HBV infection using the technology platforms of both companies. Under the terms of the agreement, Dicerna will receive $200M in an initial upfront payment and may be eligible to receive up to an additional $1.47B over time for the achievement of specified development, regulatory and commercial milestones. In addition, Dicerna may be eligible to receive royalties based on potential product sales of DCR-HBVS. Dicerna retains an option to co-fund pivotal development of DCR-HBVS worldwide, which if exercised, entitles Dicerna to receive enhanced royalties and co-promote products including DCR-HBVS in the U.S. Dicerna and Roche also agreed to collaborate on the research and development of additional therapies targeting multiple human and viral genes implicated in chronic HBV infection, using technology from both companies, for which Dicerna is eligible to receive additional milestones and royalties on any potential products. The transaction is subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions.

06:38 EDT Marathon Petroleum, MPLX name Michael Hennigan as CEO of MPLX GP - Marathon Petroleum Corporation (MPC) and MPLX LP (MPLX) announced that Gregory J. Goff, executive vice chairman of MPC and a member of each of the boards of directors of MPC and MPLX's general partner, has elected to retire effective December 31, 2019. In addition, Michael J. Hennigan, current president of MPLX GP LLC, has been appointed chief executive officer of the same organization, effective November 1, 2019. Goff was named executive vice chairman upon the closing of MPC's strategic combination with Andeavor in October 2018, and he has served on the board of directors of both MPC and MPLX. Goff will retire from both boards concurrent with his retirement and Frank M. Semple will succeed Goff as a member of the MPC board. Hennigan succeeds Gary R. Heminger as CEO of the general partner of MPLX. Heminger will remain chairman of the board of MPLX GP LLC.

06:26 EDT Cigna sees 2020 Health Services' adjusted pharmacy scripts up 25M-35M - Health Services' projected 2020 retention rate for the 2019 selling season for pharmacy services is 97%. Health Services' adjusted pharmacy scripts are expected to grow 25M-35M scripts organically in 2020.

06:23 EDT Marathon Petroleum forms special committee to enhance midstream review - Marathon Petroleum announced its intent to form a special committee of the Board to enhance its evaluation of potential value-creating options for the Midstream business. Among other aspects, the special Board committee will analyze the strategic fit of assets with MPC, the ability to realize full valuation credit for midstream earnings and cash flow, balance sheet impacts including liquidity and credit ratings, transaction tax impacts, separation costs, and overall complexity. Independent Director J. Mike Stice will lead the special committee charged with this enhanced evaluation of midstream alternatives. MPC's plan to separate Speedway and to continue evaluating its Midstream business are key elements of the next phase in the company's long track record of taking transformative action to drive shareholder value. Since becoming a public company, MPC has returned nearly $21B in capital and has delivered approximately 323% of total shareholder returns, nearly double the S&P 500 returns during that period. "We will execute on the separation of Speedway and evaluate opportunities to unlock the value of Midstream, while continuing to optimize the larger combined business and progress the realization of our targeted synergies. Our goal has been, and continues to be, maximizing shareholder value over the long term," Heminger concluded.

06:21 EDT Marathon Petroleum announces intention to spin off Speedway

06:17 EDT TRI Pointe expects delivery of 73%-77% of its 2,312 home backlog in Q4 - Expects its average sales price to be $620K for both Q4 and FY19. The company expects its homebuilding gross margin percentage to be in a range of 20.5%-21.5% for Q4, resulting in a full year homebuilding gross margin percentage of 19%-20%. The company anticipates its SG&A expense as a percentage of homes sales revenue will be in a range of 9.2%-9.6% for Q4, resulting in a full year SG&A expense as a percentage of homes sales revenue in a range of 11% to 12%.

06:14 EDT Murphy Oil sees Q4 production 198 to 206 MBOEPD - For the fourth quarter, Murphy estimates total production of 198 to 206 MBOEPD, comprised of 69% liquids. Full year production is expected to be in the range of 174 to 178 MBOEPD, excluding noncontrolling interest.

06:13 EDT MGM Resorts looking to sell MGM Grand in Las Vegas, company says - On Wednesday's earnings conference call, MGM Resorts noted that earlier this month it agreed to a sale-leaseback of the Bellagio and an outright sale of Circus Circus on the Las Vegas Strip. CEO Jim Murren commented that "These transactions were key steps, but by no means the end of our journey." He added that "The Bellagio real estate transaction represents more to us than a smart financial deal. It provides a likely blueprint for the future." Murren said any deal reached for MGM Grand would close in early 2020.

06:08 EDT Dunkin' Brands reports Q3 Dunkin' U.S. SSS growth of 1.5% - Third quarter highlights include Dunkin' U.S. comparable store sales growth of 1.5% and Baskin-Robbins U.S. comparable store sales growth of 3.6%.

05:41 EDT Fiat Chrysler, Peugeot agree to work toward combination - The supervisory board of Peugeot S.A. (PUGOY) and the board of FCA N.V. (FCAU) have each unanimously agreed to work towards a full combination of their respective businesses by way of a 50/50 merger. Both boards have given the mandate to their respective teams to finalize the discussions to reach a binding Memorandum of Understanding in the coming weeks.The plan to combine the Groupe PSA and FCA businesses follows intensive discussions between the senior managements of the two companies. Both share the conviction that there is compelling logic for a bold and decisive move that would create an industry leader with the scale, capabilities and resources to capture successfully the opportunities and manage effectively the challenges of the new era in mobility. The proposed combination would create the 4th largest global OEM in terms of unit sales, 8.7M vehicles, with combined revenues of nearly EUR 170B and recurring operating profit of over EUR 11B on a simple aggregated basis of 2018 results excluding Magneti Marelli and Faurecia. The significant value accretion resulting from the transaction is estimated to be approximately EUR 3.7B in annual run-rate synergies derived principally from a more efficient allocation of resources for large-scale investments in vehicle platforms, powertrain and technology and from the enhanced purchasing capability inherent in the combined group's new scale. These synergy estimates are not based on any plant closures. It is projected that 80% of the synergies would be achieved after 4 years. The total one-time cost of achieving the synergies is estimated at EUR 2.8B. The shareholders of each company would own 50% of the equity of the newly combined group and would therefore share equally in the benefits arising from the combination. The transaction would be affected by way of a merger under a Dutch parent company and the governance structure of the new company would be balanced between the contributing shareholders, with the majority of the directors being independent. The board would be composed of 11 members. Five board members would be nominated by FCA and five would be nominated by Groupe PSA. The CEO would be Carlos Tavares for an initial term of five years and he would also be a member of the board. The new group's Dutch-domiciled parent company would be listed on Euronext, the Borsa Italiana, and the New York Stock Exchange and would continue to maintain significant presences in the current operating head-office locations in France, Italy and the U.S. It is proposed that the by-laws of the new combined company would provide that the loyalty voting program will not operate to grant voting rights to any single shareholder in the Shareholders Meeting exceeding 30%4 of the total votes cast. It is also foreseen that there would be no carry over of existing double voting rights but that new double voting rights would accrue after a three-year holding period after completion of the merger. A standstill in respect of the shareholdings of EXOR N.V., Bpifrance Participations SA, DFG and the Peugeot Family would apply for a period of 7 years following completion of the merger. EXOR, Bpifrance Participations and the Peugeot Family would be subject to a 3-year lock-up in respect of their shareholdings except that the Peugeot Family would be permitted to increase its shareholding by up to 2.5% during the first 3 years following the closing, only by acquiring shares from Bpifrance Participations and DFG. Prior to the completion of the transaction, FCA would distribute to its shareholders a special dividend of EUR 5.5B, as well as its shareholding in Comau. In addition, prior to completion, Peugeot would distribute to its shareholders its 46% stake in Faurecia. This would enable the combined groups' shareholders to equally share in the synergies and benefits that would flow from a merger while recognizing the significant value of FCA's differentiated platform in North America and strong position in Latin America, including its market-leading margins in those regions. It would also reflect the added value that FCA's higher-end global brands Alfa Romeo and Maserati would bring given their substantial development potential.

05:34 EDT Fiat Chrysler, Peugeot agree to work toward combination

05:14 EDT Fluor awarded engineering services agreement by KPO in Kazakhstan - Fluor announced that its consortium with the Branch of KMG Engineering LLP KazNIPImunaigas was awarded a three-year engineering services agreement, plus two potential one-year extensions, by Karachaganak Petroleum Operating B.V., or KPO, for projects at its Karachaganak Field in Kazakhstan. Fluor booked the undisclosed contract value in the third quarter of 2019. Fluor's scope of work includes feasibility studies, front-end engineering design and other engineering services. Fluor plans to open an office in Aksai for dedicated project personnel with scalable accommodation to meet all engineering requirements. An engineering team in Fluor's Farnborough, UK office as well as global subject matter experts will also support project needs.